Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 1, 2013

Novartis, Oxford BioMedica Ink Production Agreement for Lentiviral Gene Therapy

  • Oxford BioMedica has agreed to produce clinical trial material using its LentiVector® gene delivery technology for Novartis’ use as part of its CTL019 leukemia program, a collaboration with scientists at the University of Pennsylvania, the company announced today.

    Through this production agreement, Oxford BioMedica will be responsible for manufacturing a lentiviral vector-encoding CTL019 technology, which Novartis et al., will use to transduce patients’ T-cells ex vivo before they are reinfused. In its announcement, Oxford BioMedica notes that CTL019 targets the protein CD19, which is associated with a number of B-cell malignancies, including chronic lymphocytic leukemia, B-cell acute lymphocytic leukemia, and diffuse large B-cell lymphoma.

    Under the terms of the agreement, Oxford BioMedica stands to make anywhere from £2.5 million ($3.9 million) to £4 million ($6.2 million) during the first year of collaboration, the firm added.

    According to Edison Research Investment, Oxford BioMedica’s deal with Novartis is expected to raise the gene-based therapy firm’s valuation from £58.5 million ($91 million) to £60.1 million ($93.6 million) in that same timeframe.

    Edison calls the transaction “an attractive deal of Oxford BioMedica,” adding that it could eventually lead to a longer-term supply agreement.

    In a statement, Oxford BioMedica CEO John Dawson said that Novartis’ “strategic investment in our specialist manufacturing capabilities is a pivotal step towards building a financially self-sustaining business,” adding that “this collaboration is an example of how we can commercialize our expertise.”



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »